Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest & Investment Income (2016 - 2019)

Corcept Therapeutics' Interest & Investment Income history spans 4 years, with the latest figure at $1.1 million for Q1 2019.

  • For Q1 2019, Interest & Investment Income rose 273.13% year-over-year to $1.1 million; the TTM value through Mar 2019 reached $3.5 million, up 636.17%, while the annual FY2022 figure was $3.6 million, 572.4% up from the prior year.
  • Interest & Investment Income for Q1 2019 was $1.1 million at Corcept Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.1 million in Q1 2019 and bottomed at -$487000.0 in Q3 2016.
  • The 4-year median for Interest & Investment Income is $241000.0 (2017), against an average of $321800.0.
  • The largest annual shift saw Interest & Investment Income surged 117.66% in 2017 before it surged 782.56% in 2018.
  • A 4-year view of Interest & Investment Income shows it stood at -$487000.0 in 2016, then soared by 138.6% to $188000.0 in 2017, then soared by 454.26% to $1.0 million in 2018, then rose by 5.28% to $1.1 million in 2019.
  • Per Business Quant, the three most recent readings for CORT's Interest & Investment Income are $1.1 million (Q1 2019), $1.0 million (Q4 2018), and $759000.0 (Q3 2018).